New U.S. patent granted for Nventa's Coval(TM) HPV fusions to treat patients with HPV-related diseases

    SAN DIEGO, CA, Oct. 29 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) announced today that the U.S. Patent and Trademark Office has issued
Patent Number 7,262,014 to Nventa covering compositions and methods for
inducing or enhancing immune responses to a human papillomavirus (HPV) antigen
with or without the use of an adjuvant. The Company's CoVal(TM) HPV protein
fusions are being developed to treat patients with HPV-related diseases.
    This new U.S. patent provides for a method of treating a tumor expressing
an HPV antigen through the administration of an effective amount of a
composition comprised of an HPV antigen joined or fused to a stress protein.
This patent provides additional patent exclusivity for HspE7, the Company's
investigational therapeutic vaccine, and future HPV fusions through February
    Gregory M. McKee, President and Chief Executive Officer at Nventa
commented: "The issuance of this patent protecting the use of our HPV
CoVal(TM) protein fusions to treat HPV-related diseases strengthens our
intellectual property portfolio and, we believe, adds further value to our
HspE7 program, which is currently in Phase 1 clinical development."

    About Nventa Biopharmaceuticals Corporation:
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The Company is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa
Biopharmaceuticals Corporation, please visit the Company's website located at

    This press release contains statements which, to the extent that they are
not recitations of historical fact may constitute forward-looking information
under applicable Canadian securities legislation or forward-looking statements
within the meaning of the Unites States Private Securities Litigation Reform
Act of 1995. Such forward-looking statements or information may include
financial and other projections as well as statements regarding the Company's
future plans, objectives, performance, revenues, growth, profits, operating
expenses or the Company's underlying assumptions. The words "may", "would",
"could", "will", "likely", "expect," "anticipate," "intend", "plan",
"forecast", "project", "estimate" and "believe" or other similar words and
phrases are intended to identify forward-looking statements or information.
Persons reading this press release are cautioned that such statements or
information are only predictions, and that the Company's actual future results
or performance may be materially different.
    Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning the coverage
provided by this patent and our patent exclusivity for HspE7 and future HPV
    Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially different from
any future results, events or developments expressed or implied by such
forward-looking statements or information. Such factors include, among others,
potential challenges to our patents, potential patent awards to third parties
and other factors as described in detail in our filings with the Canadian
securities regulatory authorities at Given these risks and
uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement.
    Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include, among
others, that challenges to our patents, if any, will be unsuccessful and that
third parties will not obtain patents covering HPV fusions.
    For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities, including our 2006 Annual
Information Form filed on SEDAR at Historical filings
relating to the Company prior to the completion of the Company's March 23,
2006 corporate reorganization, including Stressgen's 2005 Annual Information
Form dated March 16, 2006 may be reviewed on SEDAR at
under the SEDAR profile GVIC Publications Ltd.
    All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any intention
or obligation to revise or update such forward-looking statements and
information to reflect subsequent events or circumstances, except as required
by law.

    %SEDAR: 00023483E

For further information:

For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890